Navigation Links
Isis Reports Preclinical Data Supporting Liver Safety of ISIS 301012
Date:10/6/2007

- Results of animal studies distinguish liver effects of apoB inhibition

from MTP inhibition and support liver safety of ISIS 301012 - Favorable changes in liver fat metabolism associated with apoB inhibition

but not MTP inhibition - Results presented in an oral session today at DALM Symposium in New York

City - Isis will host a conference call on Monday, October 8, at 8:00 a.m. E.T.

at http://www.isispharm.com

CARLSBAD, Calif., Oct. 6 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced new results of preclinical studies reaffirming the safety profile of ISIS 301012 and enhancing the understanding of its activity in the liver presented by Richard Lee, Ph.D. of Isis in a 3:45 p.m. oral session today at the Drugs Affecting Lipid Metabolism (DALM) XVI International Symposium in New York City. Isis will host a conference call Monday morning at 8:00 a.m. E.T. to discuss these results along with results of Phase 2 studies of ISIS 301012 presented at DALM.

The preclinical data presented provide a mechanistic explanation for Isis' previous observations that, in mice and monkeys, treatment with antisense inhibitors of apolipoprotein B-100 (apoB) is associated with reduced liver fat content. This observation is in contrast to the effects of either small molecule or antisense inhibitors of microsomal triglyceride transfer protein (MTP), another component of the cholesterol export pathway, which cause severe liver fat accumulation in the same animal models.

In the study reported today at DALM, Isis demonstrated that apoB inhibit
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... , May 16, 2013  PTC Therapeutics, Inc., ... on Form S-1 with the U.S. Securities and Exchange ... of its common stock. The number of shares to ... have not been determined. (Logo:  http://photos.prnewswire.com/prnh/20010919/PTCLOGO ... are acting as joint book-running managers for the offering. ...
(Date:5/16/2013)...  Today, the National Patient Advocate Foundation acknowledges that ... Representatives recently approved a bill that would prohibit insurers ... out-of-pocket fees for newer, more expensive oral anti-cancer drugs ... severe side-effects. However, the bill was amended to include ... to be a barrier to patients with cancer and ...
(Date:5/16/2013)... , May 16, 2013  Alere Inc. (NYSE: ... charge of their health at home through the merger of ... of $3.00 per share on its Series B Convertible Perpetual ... 15, 2013 to holders of record of Series B stock ... Such payment will cover the amount of all dividends ...
Breaking Medicine Technology:PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering 2National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill 2National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill 3
(Date:5/18/2013)... May 18, 2013 The Communities of ... special places we call home. These are the townships, villages ... are the locations where the people are friendly and neighbors ... viewers off the highways and shares the best in both ... nations with an American sports and film celebrity. It airs ...
(Date:5/18/2013)... TheBeautyPlace.com answers important questions about the hairloss ... a result of stress, nutrient deficiency or wearing a ... of men suffer from male patterned baldness. ... hair transplant surgery, but additionally carries a hair care ... Bosley Professional Strength. Their product line is a five-step ...
(Date:5/18/2013)... Although obesity is associated with an increased ... and esophageal adenocarcinoma, a type of esophageal cancer, is ... reported on Cancer.gov, last reviewed in January 2012, ... as those of normal and healthy weight to develop ... esophageal cancer is not well understood, it is now ...
(Date:5/18/2013)... Adolescents, especially young males, who experiment with ... are landing in emergency rooms across America. ... with a new treatment program for those addicted ... from the National Institute on Drug Abuse, synthetic marijuana ... teenagers. In 2012, 11 percent of high school seniors ...
(Date:5/18/2013)... 18, 2013 Rio Salon and Spa, ... a stylish renovation that features tranquil, Eastern Asian influenced ... the ground up, this Morro Bay day spa ... soothing colors and comfortable spa beds. Additional salon stations ... Apilus epilator machine. The shampoo area has been ...
Breaking Medicine News(10 mins):Health News:Communities of Distinction TV Presents "A Place to Call Home" Segment 2Health News:TheBeautyPlace.com Features the Two New Best-Selling Hairloss Products: Bosley Professional Strength and Nioxin Systems 2Health News:TheBeautyPlace.com Features the Two New Best-Selling Hairloss Products: Bosley Professional Strength and Nioxin Systems 3Health News:hCGtreatments / Diet Doc Hcg Diets & Weight Loss Plans Announces New Prescription Hcg Diet Plans Designed to Trim Inches and Thus Reduce the Risk of Esophageal Cancer 2Health News:hCGtreatments / Diet Doc Hcg Diets & Weight Loss Plans Announces New Prescription Hcg Diet Plans Designed to Trim Inches and Thus Reduce the Risk of Esophageal Cancer 3Health News:Spice Addiction Treatment and Synthetic Marijuana Drug Rehab Announced by Recovery Associates 2Health News:Rio Salon and Spa, a Beauty Salon in Morro Bay, Undergoes Makeover 2
... Quantum Group,(Amex: QGP ) (http://www.QuantumMD.com ) ... become a third party administrator (TPA) with the ... company, Renaissance,Administrative Services, Inc. (RASI), to provide administrative ... A TPA provides an outsourced solution to ...
... low-sodium diet does not appear to have any appreciable ... new research. , "Despite the clear benefit of a ... therapeutic benefit in the use of a low-sodium dieton ... K. Pogson, M.R.C.P., clinical research fellow at the University ...
... Magnetic Resonance Imaging (MRI), and Broadlane’s clients awarded the High-Field Open ... ... Dallas, TX (PRWEB) July 15, 2008 -– Broadlane recently held ... Broadlane’s clients awarded the High-Field Open MRI contract to Hitachi Medical ...
... Obesity expert Sanford Siegal, D.O., M.D., known to generations as the ... 9th , ... McLean, VA (PRWEB) July 15, 2008 ... Dr. Siegal's® COOKIE DIET™ hunger-controlling foods and operator of seven ...
... full-day kindergarten have slightly better reading and math skills ... benefits diminish soon after the children leave kindergarten. This ... poverty and the quality of children,s home environments. , ... researchers at the University of Pittsburgh and Loyola University ...
... 14 Sun Pharmaceutical Industries,Ltd. (Reuters: SUN.BO, Bloomberg: ... its subsidiary, Alkaloida Chemical Company Exclusive Group,Ltd. (Alkaloida), ... Offer for,purchase of all outstanding Ordinary Shares of ... extended to 5:00 p.m., New York,City time, on ...
Cached Medicine News:Health News:The Quantum Group Files TPA Application 2Health News:The Quantum Group Files TPA Application 3Health News:Low-sodium advice for asthmatics should be taken with a grain of salt 2Health News:Broadlane's Live Group Buy Awards High-Field Open MRI Contract to Hitachi Medical Systems America Inc. 2Health News:Broadlane's Live Group Buy Awards High-Field Open MRI Contract to Hitachi Medical Systems America Inc. 3Health News:Broadlane's Live Group Buy Awards High-Field Open MRI Contract to Hitachi Medical Systems America Inc. 4Health News:Eighth Dr. Siegal's COOKIE DIET Retail Location Opens August 1st at Tysons Corner Center Near Washington, DC 2Health News:Eighth Dr. Siegal's COOKIE DIET Retail Location Opens August 1st at Tysons Corner Center Near Washington, DC 3Health News:Full-day kindergarteners' reading, math gains fade by 3rd grade 2Health News:Sun Pharma Extends Tender Offer for Taro 2
2 mm wide tip with 1 mm by 4 mm eye. Curved shaft and ring handle with polished finish....
Straight iris forceps. Insulated....
Hardy bayonet forceps with stops. Insulated....
Cushing forceps. Insulated....
Medicine Products: